PRESIDENT OF BOARD, ADOCIA Pharmaceutical Company
Biotechnology
CLINICAL RESEARCH
France
Gerard Soula holds a Ph.D. in Organic chemistry, graduated in IAE (Aix Marseille). He founded Flamel Technologies (in 1990), a biotech Company specialized in Drug Delivery and listed on Nasdaq. He was there CEO and Director of Research until June 2005. When he left, Flamel had 250 employees, $100M cash in bank and a market capitalization of $500M. Flamel Technologies’ success is based on the performances of its platforms, Micropump and Medusa. Furthermore, Gérard Soula has a strong track record in negotiating license agreements in innovating technologies with big pharma groups (Novo Nordisk, Bristol Myers Squibb, GlaxoSmithKline etc).
Organic chemistry